Quantitative unbiased analysis of endogenous metabolites from cells, tissues, or fluids - metabolomics, has become an integral part of functional genomics efforts lending itself as a tool for clinical diagnostics, toxicology, agriculture, biofuels, and understanding fundamental biochemistry. Where the genome and proteome represent upstream biochemical events, the metabolites correlate with the most downstream biochemistry and therefore most closely represent the phenotype. This has been proven by the broad success of metabolite analysis in clinical diagnostics and pathogenesis. We have developed a platform to enable these analyses called XCMS, XCMS allows for alignment, statistical evaluation, and metabolite characterization from mass spectrometry data. In addition we have constructed METLIN currently the largest online metabolite MS/MS database. It is worth noting that XCMS, and related papers, enables the initial characterization of endogenous and exogenous metabolites, and has been cited in over a 1200 articles.
Citation Format: Gary Siuzdak. XCMS cloud-based metabolomics: A platform for the cancer biologist. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr ED04-02.
- ©2013 American Association for Cancer Research.